Resilience already has a number of projects underway this year , including a partnership with the US Department of Defense for the development of a novel antibody treatment capable of responding to the Botulinum neurotoxin , more commonly known as Botox . “ We ’ re handling the project from phase one of development , all the way through to commercial manufacturing ,” Rahul explains . “ The hope is that the antibodies could be used to treat soldiers subjected to toxins of that variety .
“ We ’ re also working with the Parker Institute for Cancer Immunotherapy , one of the most prestigious organizations within its field , and home to a network of leading immunotherapy researchers ,” he adds . “ Through the cultivation of that network , the Institute ’ s aim is to develop immunotherapy cancer products more effectively . Our contribution is to offer our expertise and knowledge of manufacturing , in combination with the Institute ’ s knowledge of biology and medicine , in order to further accelerate the development of much-needed drugs for the benefit of patients , leveraging our complementary skill sets . Likewise , we ’ re also working with MD Anderson , another of the world ’ s leading cancer centers , to improve and accelerate the use of cell therapies in treatment . Together , we ’ ve established a joint venture , the Cell Therapy Manufacturing Center ( CTMC ), in Houston , Texas , where they can focus on biology and medicine , while we take care of manufacturing .”
Investing in innovation
Each of Resilience ’ s partnerships is testament to the company ’ s ongoing commitment to the development of new solutions within biomanufacturing . “ Innovation is necessary ,” Rahul argues . “ To achieve it , we have to do our research , whether it ’ s in the field of gene therapy , viral vector production , or delivery vehicles for genomic medicines . The industry has already realised the concept of MRNA vaccines , but even there , we cannot be satisfied with the status quo ; we need to make them better . If the vaccines of today need to be kept at sub-zero temperatures , the vaccines of tomorrow will be room-temperature stable . Other medicines are expensive ; the challenge there is to produce them at a lower cost .”
Despite its successful track record thus far , Rahul is also keen to emphasize the need for vigilance . “ Pandemics are coming fast and furious ,” he points out . “ We ’ re just about coming to the end of Covid-19 , and we ’ re already dealing with Monkeypox as our next potential threat . After that , there ’ s no telling what the next threat will be , or where it will come from . If we don ’ t take on board the lessons of the last couple of years and
128